Impact of Specimen Type and Specimen Number on HER2 Status in Gastroesophageal Junction and Gastric Adenocarcinoma

2019 ◽  
Vol 151 (5) ◽  
pp. 461-468 ◽  
Author(s):  
Aaron R Huber ◽  
Brandon Buscaglia ◽  
Brooke R Koltz ◽  
Jill Henry ◽  
Loralee McMahon ◽  
...  
Keyword(s):  
Gastric Adenocarcinoma ◽  
Gastroesophageal Junction ◽  
Her2 Status ◽  
Specimen Type ◽  
Specimen Number

scholarly journals HER2 Receptor Overexpression in Gastric Adenocarcinoma A Study about a Sampling of 50 Cases in Dakar

2019 ◽  
Vol 4 (3) ◽  
pp. 1-6
Author(s):  
Bentefouet TL
Keyword(s):  
Gastric Adenocarcinoma ◽  
Poor Prognosis ◽  
Gastroesophageal Junction ◽  
Immunohistochemical Method ◽  
Clinicopathological Parameters ◽  
Her2 Status ◽  
Her2 Overexpression ◽  
Her2 Receptor ◽  
Male Predominance ◽  
One Year

ntroduction: HER2 receptor overexpression in gastric or gastroesophageal junction (GOJ) adenocarcinoma is a factor of poor prognosis detected in 7 to 34% of gastric and GOJ adenocarcinomas. The objective of this study was to evaluate the overexpression of the HER2 receptor in gastric adenocarcinomas in Dakar, and to investigate the correlation between HER2 overexpression and clinicopathological parameters. Patients and method: This is a retrospective, descriptive and analytical study that was conducted over a one - year period; from 1 January 2016 to 31 December 2017. It involves 50 cases of gastric or GOJ adenocarcinomas histologically confirmed on biopsy samplings, collected within pathological anatomy and cytology services in Dakar (HALD a nd HOGGY). The study of HER2 receptor overexpression was performed on tumor samples put in buffered formalin and embedded in paraffin using the immunohistochemical method. Results: The average age was 58.18 ± 14.6 years. A male predominance was observed, w ith a gender ratio of 1.27. Tumors were ulcero budding in 76% of cases. They were found at the gastric level in 92% of the surveyed cases, and at the gastroesophageal junction in 8% of them. Adenocarcinomas were of tubulous type in 76% of cases, and they w ere markedly differentiated in 54% of cases. At immunohistochemical study, the positivity rate of the HER2 was 8% out of the 50 cases that were tested. There was no correlation between HER2 overexpression and those clinicopathological parameters . Con clusion: HER2 is a factor of poor prognosis but it is also a therapeutic response factor to anti - HER2s. Assessment of the HER2 status should be systematic in all cases of gastric adenocarcinoma; and it requires a multidisciplinary approach.

A phase Ib/II, multicenter, open-label, dose-escalation, and dose-expansion study evaluating trastuzumab deruxtecan (T-DXd, DS-8201) monotherapy and combinations in patients with HER2-overexpressing gastric cancer (DESTINY-Gastric03).

2021 ◽  
Vol 39 (3_suppl) ◽  
pp. TPS261-TPS261
Author(s):  
Yelena Y. Janjigian ◽  
Natasha Viglianti ◽  
Feng Liu ◽  
Ariadna Mendoza-Naranjo ◽  
Liz Croydon
Keyword(s):  
Gastric Cancer ◽  
Dose Escalation ◽  
Topoisomerase I ◽  
Gastroesophageal Junction ◽  
Objective Response ◽  
Locally Advanced ◽  
Metastatic Gastric Cancer ◽  
Her2 Status ◽  
Open Label ◽  
Phase 1B

TPS261 Background: For patients (pts) with HER2-overexpressing metastatic gastric cancer, trastuzumab + chemotherapy is a standard first-line option but provides only a modest overall survival (OS) benefit vs chemotherapy. T-DXd is an antibody-drug conjugate consisting of an anti-HER2 antibody, cleavable tetrapeptide-based linker, and a membrane-permeable topoisomerase I inhibitor payload. Results from a phase 1 trial showed promising antitumor activity (confirmed objective response rate [ORR], 43.2%) in pts with heavily pretreated HER2+ metastatic gastric cancer who received T-DXd (5.4 or 6.4 mg/kg; Shitara K, et al. Lancet Oncol. 2019;20:827-836). Here we describe the phase 1b/2 DESTINY-Gastric03 trial (NCT04379596) evaluating T-DXd monotherapy and combinations in pts with HER2-overexpressing gastric cancer. Methods: This is an open-label, multicenter, 2-part, phase 1b/2 study in pts with HER2-overexpressing (immunohistochemistry [IHC] 3+ or IHC 2+/in situ hybridization positive) locally advanced, unresectable or metastatic gastric or gastroesophageal junction cancer. In part 1 (dose escalation), pts who had received prior trastuzumab-containing therapy will be assigned to 1 of 5 arms: (1) T-DXd + 5-fluorouracil (5-FU); (2) T-DXd + capecitabine (C); (3) T-DXd + durvalumab; (4) T-DXd + 5-FU or C + oxaliplatin (Ox); or (5) T-DXd + 5-FU or C + durvalumab. In part 2 (dose expansion), pts with no prior treatment for metastatic disease will be randomized across 4 arms: (1) T-DXd; (2) trastuzumab + 5-FU or C + Ox or cisplatin; (3) T-DXd + 5-FU or C ± Ox; or (4) T-DXd + 5-FU or C + durvalumab. In part 2, pts will be stratified by HER2 status. Primary endpoints are safety, determination of recommended phase 2 doses (part 1), and investigator-assessed confirmed ORR per RECIST v1.1 (part 2). Secondary endpoints include confirmed ORR (part 1), disease control rate, duration of response, progression-free survival (all per investigator), OS, safety (part 2), pharmacokinetics, and immunogenicity. Clinical trial information: NCT04379596.

scholarly journals Gastric Carcinoma with Osteoclast-Like Giant Cells Coexisting with Gastrointestinal Spindle Cell Tumor

2013 ◽  
Vol 2013 ◽  
pp. 1-4 ◽  
Author(s):  
Christos Poulios ◽  
Triantafyllia Koletsa ◽  
Antonis Goulas ◽  
Georgia Karayannopoulou ◽  
Eleni Vrettou ◽  
...  
Keyword(s):  
Gastric Adenocarcinoma ◽  
Spindle Cell ◽  
Gastroesophageal Junction ◽  
Subtotal Gastrectomy ◽  
Giant Cells ◽  
Gastric Fundus ◽  
Gastric Carcinomas ◽  
Spindle Cell Lesion ◽  
Exophytic Tumor ◽  
Upper Abdominal

Reactive multinucleated osteoclast-like giant cells (OGCs) have been described in a variety of neoplasms but rarely in gastric carcinomas. Reported herein is a case of an 81-year-old Caucasian male presented with upper abdominal pain and dysphagia. Esophagogastroscopy revealed an ulcerative mass and a specimen of subtotal gastrectomy and lower esophagectomy was sent for histologic examination. At the gastroesophageal junction an exophytic tumor, measured 2.2 cm in greatest diameter, was observed. Sections from the tumor showed gastric adenocarcinoma, stage pT1bpN0. Diffusely among the neoplastic cells multinucleated giant cells, resembling osteoclasts, were observed, which were positive for CD68, lysozyme, and vimentin and negative for AE1/AE3, CK8/18, hHCG, and LMP1. Moreover, in a random section from the gastric fundus, a spindle cell lesion, sized 0.6 cm, was revealed, which was positive for CD117 and CD34 antigens and was diagnosed as gastrointestinal stromal tumor (GIST). The presence of OGCs is an uncommon finding in gastric carcinomas and by analogy to breast and pancreatic carcinomas it could characterize a rare distinct morphological variant of gastric adenocarcinoma. Due to the limited number of the reported cases, the prognostic value of OGCs is under discussion. Furthermore, pathologists should be aware that incidental GIST may accompany any tumor.

scholarly journals The Reliability of Endoscopic Biopsies in Assessing HER2 Status in Gastric and Gastroesophageal Junction Cancer: A Study Comparing Biopsies with Surgical Samples

2013 ◽  
Vol 6 (1) ◽  
pp. 10-16 ◽  
Author(s):  
Federica Grillo ◽  
Matteo Fassan ◽  
Chiara Ceccaroli ◽  
Cinzia Giacometti ◽  
Monica Curto ◽  
...  
Keyword(s):  
Gastroesophageal Junction ◽  
Her2 Status ◽  
Gastroesophageal Junction Cancer ◽  
Endoscopic Biopsies

Seventh edition (2010) of gastric adenocarcinoma AJCC staging system: Is there room for improvement?

2012 ◽  
Vol 30 (4_suppl) ◽  
pp. 77-77
Author(s):  
Manali I. Patel ◽  
Kim F Rhoads ◽  
Yifei Ma ◽  
James M. Ford ◽  
Jeffrey A. Norton ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Gastric Adenocarcinoma ◽  
Health Planning ◽  
Gastroesophageal Junction ◽  
Staging System ◽  
Rank Test ◽  
Population Database ◽  
Curative Intent ◽  
Ajcc Staging System ◽  
Ajcc Staging

77 Background: The gastric cancer AJCC staging system recently underwent significant modifications of the T and N categories as well as stage groupings. The new system has not been validated on a US population database, but studies on Asian patients have reported no difference in survival between stages IB and IIA, as well as IIB and IIIA. Methods: California Cancer Registry data linked to Office of Statewide Health Planning and Development discharge abstracts were used to identify patients with gastric adenocarcinoma (gastroesophageal junction tumors excluded) who underwent curative-intent surgical resection from 2002 to 2006. AJCC stage was reclassified based on the 7th edition. Disease-specific survival (DSS) probabilities were calculated using the Kaplan-Meier method and compared using the log rank test. Results: Of 4,985 patients identified, 2,262 had complete pathologic data and known cause of death. Median age was 70 years and 60% were males. Median number of examined lymph nodes was 12 and 39% of patients received adjuvant chemotherapy. The 7th edition AJCC system did not distinguish outcome adequately between stages IB and IIA (P = .25), or IIB and IIIA (P = .33, Table ). By merging stage II into one category and moving T2N1 to stage IB and T2N2, T1N3 to stage IIIA, we propose a new grouping system which showed improved discriminatory ability ( Table ). Conclusions: In this first study validating the new 7th edition AJCC staging system for gastric cancer on a US population, we found stages IB and IIA, as well as IIB and IIIA to perform similarly. We propose a revised stage grouping for the AJCC system that better discriminates between outcomes. [Table: see text]

Investigating HER2 status and polysomy 17 in gastric adenocarcinoma using multiplex ligation-dependent probe amplification.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. e15042-e15042
Author(s):  
Tao Wang ◽  
Yutaka Amemiya ◽  
Pauline Henry ◽  
Arun K Seth ◽  
Wedad Hanna ◽  
...  
Keyword(s):  
Gastric Adenocarcinoma ◽  
Her2 Status ◽  
Polysomy 17 ◽  
Dependent Probe

Prognostic factors for survival in patients with advanced gastric cancer treated with chemotherapy.

2016 ◽  
Vol 34 (4_suppl) ◽  
pp. 142-142
Author(s):  
Montserrat Mangas ◽  
Alberto Carmona Bayonas ◽  
Maria Luisa Sanchez Lorenzo ◽  
Avinash Ramchandani ◽  
Teresa Garcia ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Overall Survival ◽  
Prognostic Factors ◽  
Advanced Gastric Cancer ◽  
Group Performance ◽  
Gastroesophageal Junction ◽  
Cox Proportional Hazards Model ◽  
Her2 Status ◽  
Her2 Positive ◽  
Ecog Ps

142 Background: A prognostic model in advanced gastric cancer that integrates the Her2 status,histopathological classifications and other patient’s or treatment-dependent parameters is lacking. The aim is to identify clinicopathological factors for overall survival in a cohort of patients with advanced gastric cancer. Methods: 526 consecutive patients with advanced adenocarcinoma of the distal esophagus, gastroesophageal junction or stomach were analyzed. All patients were treated with poly-chemotherapy ( ≥ 2 drugs) at 19 Spanish and one Chilean centers between 2012 and 2015. Characteristics of patients, tumors, therapies and pathological factors, were analyzed by a Cox proportional hazards model. Results: The median overall survival was 10.3 months [95% confidence interval (CI), 9.5-11.1], and the time to progression was 6.7 months (95% CI, 6.1-7.2). Independent prognostic factors associated with overall survival were: distal non-diffuse histopathological subtype (hazard ratio, (HR) 0.73), Her2 positive 3+ (HR 0.54), Her2 positive 2+ with FISH + (HR 0.68), surgery of metastases (HR 0.34), Eastern Cooperative Group performance status (ECOG PS) 2 (HR 2.5), ECOG PS 3 (HR 7.37), and only distant lymph node metastases (HR 0.63) (Table 1). Conclusions: We have identified clinicopathological prognostic factors that could be important to stratify advanced gastric cancer, with potential implications in research and treatment. [Table: see text]

Sign in / Sign up

Export Citation Format

Share Document